MX351220B - Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada. - Google Patents

Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.

Info

Publication number
MX351220B
MX351220B MX2016015430A MX2016015430A MX351220B MX 351220 B MX351220 B MX 351220B MX 2016015430 A MX2016015430 A MX 2016015430A MX 2016015430 A MX2016015430 A MX 2016015430A MX 351220 B MX351220 B MX 351220B
Authority
MX
Mexico
Prior art keywords
factor viii
specific activity
increased specific
new variant
antihemophilic factor
Prior art date
Application number
MX2016015430A
Other languages
English (en)
Inventor
Kong Lai Chee
Kevin Stafford Roddy
Original Assignee
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH filed Critical Baxalta GmbH
Publication of MX351220B publication Critical patent/MX351220B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un polinucleótido que codifica una variante de factor VIII (FVIII) porcino con dominio B completa o parcialmente eliminando, la variante FVIII comprende una secuencia que es al menos 90% idéntica a la SEQ ID NO: 1; y desprovista de una secuencia de aminoácidos correspondiente a los aminoácidos 716 a 742 del factor VIII porcino como se representa en la Figura 2 o los aminoácidos 714 a 740 de la SEQ ID NO; 7.
MX2016015430A 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada. MX351220B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (1)

Publication Number Publication Date
MX351220B true MX351220B (es) 2017-10-05

Family

ID=46025129

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005047A MX347503B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
MX2016015430A MX351220B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013005047A MX347503B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.

Country Status (18)

Country Link
US (2) US9150637B2 (es)
EP (1) EP2635297B1 (es)
JP (1) JP5922141B2 (es)
KR (1) KR101948337B1 (es)
CN (1) CN103298483B (es)
AU (1) AU2011323236B2 (es)
BR (1) BR112013011041B1 (es)
CA (1) CA2816575C (es)
CO (1) CO6720990A2 (es)
DK (1) DK2635297T3 (es)
EA (1) EA035447B1 (es)
ES (1) ES2721478T3 (es)
IL (1) IL226158B (es)
MX (2) MX347503B (es)
MY (1) MY165089A (es)
SG (2) SG190136A1 (es)
WO (1) WO2012061689A2 (es)
ZA (1) ZA201303816B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819123T3 (es) 2015-01-30 2021-04-15 Univ Emory Proteínas del factor VIII que tienen secuencias ancestrales, vectores de expresión, y usos relacionados con ellos
EP3476860A4 (en) 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research RECOMBINANT SINGLE CHAIN FVIII AND CHEMICAL CONJUGATE THEREOF

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
EP0710288B1 (en) 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
DE69740154D1 (de) * 1996-04-24 2011-05-05 Univ Michigan Gegen Inaktivierung resistenter Faktor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU735763B2 (en) 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
CZ307715B6 (cs) 1999-02-22 2019-03-06 University Of Connecticut Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
ES2252028T3 (es) 1999-07-13 2006-05-16 Biovitrum Ab Composiciones estables del factor viii.
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
JP4634036B2 (ja) 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
AU2002364509A1 (en) 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII FACTOR WITH REDUCED IMMUNOGENICITY THROUGH MUTAGENESIS OF A2 AND C2 EPITOPES
WO2005072340A2 (en) * 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
ES2449044T3 (es) 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
EP3153181A1 (en) 2004-11-12 2017-04-12 Bayer HealthCare LLC Site-directed modification of fviii bdd
KR101542752B1 (ko) * 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
US20090271163A1 (en) 2007-12-06 2009-10-29 Wyeth Crystal structure of human factor VIII and uses thereof

Also Published As

Publication number Publication date
SG10201509149VA (en) 2015-12-30
AU2011323236A1 (en) 2013-06-06
IL226158A0 (en) 2013-06-27
EA201390654A1 (ru) 2014-01-30
CA2816575C (en) 2019-06-11
EP2635297A2 (en) 2013-09-11
WO2012061689A2 (en) 2012-05-10
EP2635297A4 (en) 2014-06-25
SG190136A1 (en) 2013-07-31
JP2013545459A (ja) 2013-12-26
US20150353625A1 (en) 2015-12-10
CN103298483B (zh) 2017-04-12
JP5922141B2 (ja) 2016-05-24
CO6720990A2 (es) 2013-07-31
MX347503B (es) 2017-04-26
MX2013005047A (es) 2013-12-06
KR101948337B1 (ko) 2019-02-14
CN103298483A (zh) 2013-09-11
EA035447B1 (ru) 2020-06-17
ES2721478T3 (es) 2019-07-31
WO2012061689A3 (en) 2012-10-04
US9150637B2 (en) 2015-10-06
KR20140114266A (ko) 2014-09-26
CA2816575A1 (en) 2012-05-10
EP2635297B1 (en) 2019-02-27
DK2635297T3 (da) 2019-05-06
US10053500B2 (en) 2018-08-21
AU2011323236B2 (en) 2017-03-30
BR112013011041A2 (pt) 2017-06-06
MY165089A (en) 2018-02-28
US20130296244A1 (en) 2013-11-07
BR112013011041B1 (pt) 2021-05-25
ZA201303816B (en) 2021-05-26
AU2011323236A8 (en) 2013-07-25
IL226158B (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
CA144362S (en) Combined dishwashing and scrubbing tool
MX2013001540A (es) Composiciones que comprende un polipeptido que tiene actividad de incremento celulolititico y un compuesto de quinona, y uso de las mismas.
ZA201206697B (en) Inverted dome to supply dose
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
IN2014DN09085A (es)
IN2014DN06104A (es)
BR112014014896A2 (pt) nova combinação
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
MX2015007727A (es) 6-cloro-3-(fenil-d5)inden-1-ona y su uso.
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
CY1117053T1 (el) Συνθεση μελιου με l-αλανυλ-l-γλουταμινη
MX351220B (es) Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX354501B (es) Ingrediente perfumante de la familia galbano.
FR2969615B1 (fr) Nouveau complexes carbeniques de platine et leur utilisation comme medicaments
IN2015DN02647A (es)
MX2013002485A (es) Fenilacetamidas y fenilpropanamidas sustituidas y su uso.
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
AU338253S (en) Retail Unloader
AU336535S (en) Medical dressing
AU2010904081A0 (en) Delivery of Fabric Care Products
UA72478U (ru) Применение полентара как средства фригопротекторного действия
GB201015030D0 (en) Healing foot creme
AU342487S (en) Inverter